Digestive Peritoneal Carcinomatosis
Conditions
Keywords
Peritoneal carcinomatosis, Biobanking, Biospecimen research, Prospective clinical database, Tissue banking, Quality of Life, various histological subtypes
Brief summary
To access to good quality biological samples is a prerequisite for high level translational research. The BIG-RENAPE study has been established by the French hyperthermic intraperitoneal chemotherapy centers involved in the management of peritoneal surface malignancies. The main BIG-RENAPE study aim is to create a large multicentric and prospective repository for biological and tissue samples, which will provide a source of materials for a wide array of health related research studies - BIG-RENAPE Biobank-based research: i) validating known and promising biomarkers; ii) identifying new predictive and prognostic factors; iii) evaluating the impact of current health care strategies; iv) standardizing diagnostic and therapeutic management through guidelines; v) developing new drugs. The BIG-RENAPE Biobank is certified according to NFS 96-900 as a service of processing, storage and transfer of high quality biological (plasma, serum, buffy coat) and tissue (formalin-fixed-paraffin-embedded) samples. Biospecimens are collected at each stage of diagnostic and therapeutic care. The patient and his derivates are anonymized and registered in a national web database reporting disease status, treatments, surgical procedures, pathological diagnosis, quality of life's assessment and long term follow-up. All participants have given their informed consent before any sample. The BIG-RENAPE study was approved by the local Ethical Committee, based on the assessed compliance to French regulatory rules.
Interventions
OTHERCollection of biospecimens and Quality of Life (QoL) assessment
Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
Sponsors
Hospices Civils de Lyon
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men / women aged over 18 years * Patients with cancer management and care for peritoneal carcinomatosis of digestive origin * Patients had histologic/radiologic confirmation of peritoneal disease * Covered by a Health System where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research; * Ability of participants to give their informed consent
Exclusion criteria
* Minor patient * Adult unable to consent * Patient refusal to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Resistance to oncological treatments | During the 3-year follow-up | Resistance to treatments (systemic and intraperitoneal chemotherapy, surgical procedures and targeted therapies) in patients treated for digestive peritoneal carcinomatosis is defined as a change of therapeutic strategy decided during a multidisciplinary meeting. The biological and tumoral factors related to resistance of oncological treatments will be identified from the laboratory tests results and histological analyses. Biospecimens types: serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care |
| Presence of biological and tumoral factors related to resistance to oncological treatments | During the 3-year follow-up | The biological and tumoral factors related to resistance of oncological treatments will be identified from the laboratory tests results and histological analyses. Biospecimens types: serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care The biological and tumoral factors related to resistance of oncological treatments will be identified from the laboratory tests results and histological analyses. Biospecimens types: serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| social characteristics of patients by MOS-SSS test, according to their therapeutic car modalities | at baseline (day 0), 1 month post baseline (M1), 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36 months | The Medical Outcomes Study Social Support Survey (MOS-SSS) is used as a self-administered measure of functional social support for chronically ill persons. The 19 items cover four domains (emotional/informational support, tangible support, positive social interaction, and affection). |
| quality of life measured by questionnaires (composite measure composed of QLQ-C30, QLQ-CR29 and QLQ-STO22 questionnaires), according to treatment strategies | at baseline (day 0), 1 month post baseline (M1) 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36 months | The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It incorporates nine multi-item scales: five functional scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and nausea and vomiting); and a global health and quality-of-life scale. The QLQ-CR29 was administered with the QLQ-C30 core questionnaire. It is meant for use among colorectal cancer patients varying in disease stage and treatment modality. The module comprises 29 questions assessing the colorectal cancer-specific symptom scales (disease symptoms, side effects of treatment) and functional scales (body image, sexuality, and future perspective). The QLQ-STO22 was administered with the QLQ-C30 core questionnaire. The QLQ-STO22 module contains 22 items regarding dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss. |
| Intensity of pain perceived by the patient measured by VAS scale | at baseline (day 0), 1 month post baseline (M1), 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36 months | The patient's perception intensity of pain is measured with a Visual Analogue Scale (VAS). |
| Presence of clinical factors related to resistance to oncological treatments. | During the 3-year follow-up | Demographic, pathological, clinical information are recorded electronically on a secured Web application and linked to biospecimens identification. |
| Presence of prognostic and predictive biomarkers related to resistance to oncological treatments . | During the 3-year follow-up | The prognostic and predictive biomarkers related to resistance of oncological treatments will be identified from the biological tumoral and clinical data. |
| behavioral characteristics of patients by HADS Scale, according to their therapeutic car modalities | at baseline (day 0), 1 month post baseline (M1), 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33 and 36 months | The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, is used to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems. |
| Presence of epidemiological and demographic determinants of delayed access to treatment induction or surgical procedure | During the 3-year follow-up | Epidemiological and demographic factors will be assessed from the prospective and clinical database. |
| Incidence of recurrence and survival | at 3 years | Impact of therapeutics strategies on the incidence of recurrence and survival |
Countries
France
Outcome results
None listed